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Abstract 
Background: More than 200 million people live in areas of highly seasonal malaria transmission where Seasonal 
Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) was recommended in 
2012 by WHO. This strategy is now implemented widely and protected more than 19 million children in 2018. It was 
previously reported that exposure to SMC reduced antibody levels to AMA1, MSP-142 and CSP, but the duration of 
exposure to SMC up to three 3 years, had no effect on antibody levels to MSP-142 and CSP.
Methods: In 2017, a cross-sectional survey was carried out 1 month after the last dose of SMC had been given to 
children aged 4–5 years randomly selected from areas where SMC had been given for 2 or 4 years during the malaria 
transmission season. A total of 461 children were enrolled, 242 children in areas where SMC had been implemented 
for 4 years and 219 children in areas where SMC had been implemented for 2 years. Antibody extracted from dry 
blood spots was used to measure IgG levels to the malaria antigens CSP, MSP-142 and AMA1 by ELISA.
Results: The prevalence of antibodies to MSP-142 was similar in children who had received SMC for 4 years com-
pared to those who had received SMC for only 2 years (85.1 vs 86.0%, ajusted odd ratio (aOR) = 1.06, 95% confidence 
intervals (CI 0.62–1.80), p = 0.80). The prevalence of antibodies to AMA-1 and to CSP was not lower in children who 
received SMC for 4 years compared to those who had received SMC for only 2 years (95.3 vs 88.8%, aOR = 3.16, 95% CI 
1.44–6.95, p = 0.004 for AMA-1; and 91.2 vs 81.9%, aOR = 3.14, 95% CI 1.70–5.76, p < 0.001 for CSP). Median antibody 
levels for anti-MSP-142 IgG were not significatively inferior in children who had received SMC for four rather than 2 
years (0.88 (IQR: 0.64–1.15) and 0.95 ((0.68–1.15), respectively), anti-CSP (1.30 (1.00–1.56) and 1.17 (0.87–1.47)), and 
anti-AMA-1 (1.45 (1.24–1.68) and 1.41 (1.17–1.64)).
Conclusion: In an area of high seasonal malaria transmission, children who had received SMC for 4 years did not had 
lower seropositivity or antibody levels to AMA1, MSP-142 and CSP compared to children who had received SMC for 
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Background
The health information system in Mali reported that in 
2018 malaria was responsible for 32% of all outpatient 
consultations in health facilities with 2.34 million clini-
cal cases of malaria [1]. Since 2012, Seasonal Malaria 
Chemoprevention (SMC) has been recommended by the 
World Health Organization (WHO) for children aged 
3–59  months living in areas of highly seasonal malaria 
transmission in this sub-region [2]. SMC consists of full 
treatment courses of sulfadoxine–pyrimethamine plus 
amodiaquine (SP + AQ) given to children 3–59  months 
of age, at monthly intervals during the malaria transmis-
sion season to maintain therapeutic anti-malarial drug 
concentrations in the blood throughout the period of 
greatest malaria risk [2]. In 2018, 19 million children in 
12 countries in Africa’s Sahel sub-region were protected 
through SMC programmes [3].
Despite the substantial benefits provided by SMC, one 
area of concern is that SMC will impair the natural acqui-
sition of protective immune responses, thereby increas-
ing the risk of disease in later years. Serological markers 
can be used to monitoring malaria immunity in areas 
where control intervention efforts have been undertaken. 
They also provide useful baseline information about the 
intensity of malaria transmission in different epidemio-
logical situations.
Early studies of SMC showed small increases in clini-
cal malaria following the cessation of a single year of the 
intervention in Mali and Burkina Faso [4, 5]. In Mozam-
bique, antibody levels to Plasmodium falciparum eryth-
rocytic-stage antigens in the first 2 years of life were not 
different after chemoprophylaxis with SP administered 
at 3, 4 and 9 months of age [6]. In Senegal, seropositiv-
ity to the blood-stage antigens AMA-1 and GLURP were 
higher in children in areas where SMC was not imple-
mented compared to those in the area where it was 
implemented although there was no significant differ-
ence between children who did or did not receive SMC 
in the area where the strategy was implemented [7]. In a 
high-transmission setting in Uganda, children randomly 
assigned to receive monthly chemoprevention with dihy-
droartemisinin-piperaquine had a greater percentage of 
infected red blood cells specific CD4 + T cells coproduc-
ing IL-2 and TNF, which were associated with protection 
from subsequent malaria and parasitaemia, and fewer 
CD4 + T cells coproducing IL-10/ IFN-γ, which were 
associated with an increased risk of malaria than control 
children [8]. A lower prevalence of seropositivity for 
MSP-119 was reported in children, who received biannual 
azithromycin preventive treatment compared to whose 
who received annual treatment in Niger [9].
In a recent study in Ouelessebougou, an area of high 
seasonal malaria transmission in Mali, the measurement 
of seroprevalence was less sensitive than measuring IgG 
levels in detecting differences between children who did 
or did not receive SMC. Exposure to SMC reduced anti-
body levels to AMA1, MSP-142 and CSP, but the duration 
of exposure to SMC up to three 3  years, had no effect 
on antibody levels to MSP-142  and CSP [10]. The study 
compared findings in children who never received SMC 
and those who received it for one, two or three years. In 
the study reported in this paper, the impact of 4 years of 
SMC compared to 2 years of SMC on the acquisition of 
antibodies to malaria antigens was assessed. Seropositiv-
ity and antibody levels to pre-erythrocytic stage (CSP) 
and blood stage (MSP-142, AMA1) antigens were meas-
ured in the two groups and compared.
Methods
Study site and procedure
The study was conducted in the health district of 
Ouelessebougou, located 80 km south of Bamako, Mali. 
The target population was children aged 3 to 59 months 
of age. SMC was implemented progressively in the dis-
trict of Ouelessebougou as described previously [10]. 
Briefly, eight of the 13 sub-districts of Ouelessebougou 
were randomly selected to receive SMC progressively 
each year, four in 2014 (year 1) two in 2015 (year 2) and 
two in 2016 (year 3). In 2016, SMC was extended to 
the entire district by the National Malaria Control Pro-
gramme (NMCP). Children in the selected areas received 
three rounds of SMC in the first year, and four rounds of 
SMC in the following years. Doses of SMC were given per 
age according to the WHO recommendation. Children 
aged 3–11 months received 75 mg of AQ given once daily 
for 3 days plus a single dose of 250/12.5 mg of SP, while 
children aged 12–59  months received 150  mg AQ base 
given once daily for 3 days and a single dose of 500/25 mg 
of SP. The single dose of SP was given on the first day at 
the same time as the first dose of AQ. SMC was adminis-
trated during the peak malaria transmission at monthly 
interval for 3 months in 2014 and 4 months the follow-
ing years. At each cycle the proportion of children who 
received SMC was estimated to 77 to 90% [11].
only 2 years suggesting that children who have received SMC for 4 years may not be more at risk of malaria after the 
cessation of SMC than children who have received SMC for a shorter period.
Keywords: Antibody to MSP-142, AMA1, CSP, Seasonal malaria chemoprevention, Seropositivity
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To assess the effect of SMC on the acquisition of anti-
bodies to P. falciparum antigens, a cross-sectional survey 
was conducted at the end of malaria transmission sea-
son in January 2018 about 6–8 weeks after the last SMC 
cycle in children aged 4–5  years. These children were 
randomly selected from the population in areas where 
SMC was given for 2 or 4 years using a two-stage sam-
pling. First, ten villages were randomly selected from 
these areas where SMC was implemented for 2 or 4 years 
and second, children in the target age ranges were ran-
domly selected using the census lists of children in these 
villages. After obtaining informed consent, finger prick 
blood samples were obtained for collection of a blood 
smear and filter paper blood spots  (Whatman® protein 
saver cards, Z761575 ALDRICH). Dried filter papers 
were stored at − 20° until use.
Laboratory methods
Recombinant proteins
All samples were assayed for Immunoglobulin G to 
recombinant proteins. The plasmodial antigens used in 
this study included recombinant AMA-1 (3D7 strain) 
[12] and MSP-142 (FVO strain) expressed in Escherichia 
coli [13] and recombinant P.  falciparum 3D7 CSP clone 
expressed in Pichia pastoris [14].
Antibody determination by ELISA
IgG was eluted from dried filter papers as previously 
described [10, 15]. Briefly, two filter paper discs of 
2.5 mm in diameter were taken from the center of a sin-
gle dried bloodspot and added into a deep well plate, 
incubated in 1120 μL of a 0.5% saponin solution at room 
temperature (RT). Plates were sealed and placed onto a 
plate shaker overnight. High-binding 96-well Immulon 
HBX4 microplates were coated with 200  ng per well of 
antigen diluted in 0.05  M carbonate-bicarbonate buffer 
and incubated overnight at 4  °C. The final serum dilu-
tion of the eluate based on estimates of the volume of 
whole blood in a 2.5 mm filter paper disc was 1:400 [15]. 
Blank, positive control (hyperimmune serum pool) and 
negative control (American malaria-naive controls) wells 
diluted 1:400 were included in each plate in duplicate at 
the same concentration as the test samples. Plates were 
blocked with 5% skim milk in PBS for 1 h 30 min at room 
temperature. Plates were washed with 0.05% Tween 20 
in PBS (PBS-Tween), samples and controls were added 
in duplicate, then incubated for 90  min at room tem-
perature. Plates were washed with 0.05% Tween 20 in 
phosphate buffered saline (PBS), anti-Human IgG-HRP 
conjugate was added and the plates were then incu-
bated for 1  h. After the plates were washed with 0.05% 
Tween in PBS, SIGMA FAST OPD tablet (Sigma-Aldrich, 
P9187-50SET) diluted in purified water was added, and 
the OD was then measured at 450  nm. Samples from 
2 year areas and 4 years areas were mixed and analysed 
together. Duplicate optical densities (ODs) of the ELISA 
results were averaged and plates were normalized using 
the positive control sample. The cut-off for seropositivity 
was defined as the mean OD plus three standard devia-
tions obtained in twelve samples of negative controls sera 
from American malaria-naïve at the same concentration 
as the test samples.
Malaria parasitaemia
Thick blood smears were stained with 10% Giemsa for 
15 min. Asexual parasite densities for P. falciparum, Plas-
modium malariae and Plasmodium ovale were counted 
against 200 white blood cells (WBCs) and converted to 
parasites/μL assuming 8000  WBC/μL. A blood smear 
was considered to have negative results if no parasites 
were identified in 100 high-power fields. Slides were 
read by an experienced certified microscopist blinded to 
the treatment allocation. 10% of slides were re-read by a 
blinded expert reader for quality control.
Statistical analysis
Data were entered and verified using DataFax. ELISA 
data were directly exported for analysis in StatView Ver-
sion 5.0.1.0 (SAS Institute Inc) and Stata (version 14). 
Antibody seropositivity was considered the primary 
endpoint for this study, and antibody levels were treated 
as secondary endpoints. Proportions were compared 
using Chi square test. ELISA OD levels were compared 
between groups using Kruskal–Wallis test. Logistic 
regression was used to compare antibody seropositiv-
ity between groups of children who received SMC for 4 
years and those who received it for 5 years, adjusting for 
age gender and malaria infection. p-values less than or 
equal to 0.05 were considered significant.
Results
Study population characteristics
A total of 461 children aged between 46–65 months were 
enrolled, 242 children in areas where SMC had been 
implemented for 4 years and 219 children in areas where 
SMC had been implemented for 2 years (Table 1). There 
were no differences in age or gender distribution between 
groups at the time that blood samples were collected. 
Prevalence of malaria infection was significantly higher 
in children who received SMC for 2 years compared to 
those who had received SMC for 4 years (33.1% versus 
19.1%, p = 0.001).
Antibody prevalence
Prevalence of seropositivity to three malarial antigens 
in children who received SMC for 2 years or for 4 years 
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are presented in Table  2. Anti-AMA1 seroprevalence 
was 88.8% in children who received SMC for 2 years and 
95.3% in children who received SMC for 4 years, and this 
difference was significant (age, gender and parasitae-
mia adjusted odd ratio (aOR) = 3.16, 95% CI 1.44–6.95, 
p = 0.004). Anti-MSP-142 seroprevalence was similar in 
children in the areas where SMC had been implemented 
for 2 years and in those resident in areas where SMC had 
been implemented for 4 years; (aOR = 1.06, 95% CI 0.62–
1.80, p = 0.80). Anti-CSP seroprevalence was 81.9% in 
children who received SMC for 2 years and significantly 
higher (91.2%) in children exposed to SMC for 4 years 
(aOR = 3.14, 95% CI 1.70–5.76, p < 0.001).
Antibodies levels
Antibody levels to AMA1, MSP-142 and CSP in children 
who received SMC for 2 years and children who received 
SMC for 4 years are presented in Fig. 1. Median IgG lev-
els to AMA1 and to CSP were significantly lower in chil-
dren who received SMC for 2 years compared to those 
who received SMC for 4 years (1.41 (IQR: 1.17–1.64) and 
1.45 (IQR: 1.24–1.68) p = 0.02 and 1.17 (IQR: 0.87–1.47) 
and 1.30 (IQR: 1.00–1.56) p = 0.0005, respectively). The 
median IgG levels to MSP-142 were similar between the 
two groups (0.95 (IQR: 0.68–1.15) and 0.88 (IQR: 0.64–
1.15), p = 0.15).
Discussion
Whether the implementation of SMC over a long period 
of time impairs the acquisition of protective immune 
responses to malaria, thereby increasing the risk of dis-
ease in later years, has been a concern. In the previous 
study [10], the exposure to SMC reduced antibody levels 
to AMA1, MSP-142 and CSP, but the duration of exposure 
to SMC from one to 3 years, had no effect on antibody 
levels to these antigens. The current study evaluated the 
effect of four consecutive years of SMC on acquisition of 
IgG antibodies to malarial antigens in children who had 
received SMC for 4 years compared to those who had 
received SMC for 2 years. It has been long known that 
naturally acquired immunity to malaria can clear para-
sites and prevent severe disease. However, the targets of 
protective immunity are unknown. In the current study, 
antibody levels to AMA-1, MSP-1 and CSP are used as 
markers of immune response to malaria exposure. The 
study showed that the prevalence and levels of IgG anti-
bodies to the three proteins were not significantly lower 
in children who had received SMC for 4 years com-
pared to those who had received SMC for 2 years. The 
Table 1 Baseline characteristics of the study children
SMC 2 years (n = 242) SMC 4 years (n = 219) p
Age (months)
 Median (min–max) 54 (46–65) 54 (46–65) 0.84
Gender
 Male (%) 49.1 51.9 0.56
 Parasite prevalence (%) 33.1 19.1 0.001
Table 2 Prevalence of  seropositivity to  three malarial antigens in  children who received seasonal malaria 
chemoprevention (SMC) for 2 years or for 4 years
SMC 2 years = received SMC for 2 years; SMC 4 years = received SMC for 4 years
a adjusted for age, gender and malaria infection
n % 95% CI Unadjusted Adjusteda
OR 95% CI p OR 95% CI p
AMA1
 SMC 2 years 215 88.8 84.5–92.8 Ref – – Ref – –
 SMC 4 years 205 95.3 92.5–98.2 2.57 1.22–5.45 0.014 3.16 1.44–6.95 0.004
MSP-142
 SMC 2 years 208 86.0 81.5–90.4 Ref – – Ref – –
 SMC 4 years 183 85.1 80.3–90.0 0.93 0.55–1.58 0.8 1.06 0.62–1.80 0.8
CSP
 SMC 2 years 196 81.9 76.0–86.0 Ref – – Ref – –
 SMC 4 years 197 91.2 87.0–95.4 2.57 1.43–4.59 0.001 3.14 1.70–5.76  < 0.001
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seroprevalence was even significantly higher for AMA1 
and CSP antibodies in the 4 years group, although the 
absolute differences were less than 10%. IgG levels to 
AMA1, MSP-142 and CSP followed the same patterns. 
It is possible that the children in the group who received 
SMC for two year group had more exposure to malaria 
earlier in life before they received SMC and that this had 
in some way down-regulated the immune response. In 
a study in The Gambia, children who have had seasonal 
malaria chemoprophylaxis with pyrimethamine and dap-
sone for three years had higher cell-mediated immune 
responses to malaria antigens, than the control children 
who did not receive seasonal malaria chemoprophylaxis 
[16].
The high proportion of seropositivity to AMA1, MSP-
142 and CSP in this study suggests that malaria exposure 
remains substantial despite SMC. Consistent with results 
from previous surveys conducted in 2016 in the same 
area [10], about one out of five children carried malaria 
parasitaemia in the areas where SMC had been imple-
mented for 4 years compared to about one third of those 
in the areas where SMC was implemented for 2 years. 
The lower prevalence of malaria in children in areas 
where SMC was implemented for 4 years may reflect 
a larger effect of a cumulative reduction in the trans-
mission in these areas. In Senegal, SMC was associated 
with reduction in transmission as shown by a reduced 
incidence of confirmed malaria in children and adults 
above the age for SMC, who did not receive SMC in the 
areas where SMC was used compared to those in the 
area where it is not [17]. Malaria parasitaemia and past 
malaria morbidity were shown to be strongly associated 
with a higher specific IgG response in a study in Sene-
gal [18]. Lower prevalence of MSP-119 seropositivity was 
reported in children who received biannual azithromy-
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Fig. 1 Antibody levels expressed as optic density in children who received SMC for 2 years and children and in those who received SMC for 4 years. 
The number of children in each group are as follow: SMC 2 years, n = 242 and SMC 4 years, n = 219
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distribution in Niger [9]. In Ugandan children, sustained 
clinical protection and higher IL-2 and TNF-α produc-
tion were reported in children with high adherence to 
monthly chemoprevention with dihydroartemisinin-
piperaquine [8].
The finding in this study are consistent with previous 
report in the same areas [10] and in Senegal [7] suggest-
ing that long-term malaria chemoprevention with SMC 
with SP + AQ has a limited impact on the development of 
antibody response against P. falciparum antigens. How-
ever, in all these studies including this one, differences in 
other factors such as malaria transmission including geo-
graphical-based heterogeneity, use of other preventive 
measures such as insecticide-treated nets and treatment-
seeking behaviours between the study areas could not be 
excluded and constitute a limitation of these studies. In 
the current study, children who have never received SMC 
could not be found and used as control due to nation 
wide implementaton of SMC starting 2016. However, 
the consistency with the previous reports in studies with 
controls who had not received SMC, was reassuring. 
Strengths of this study include the fact that the samples 
were collected at the same time in children in both areas 
with limited age range of 46 to 65 months and analysed 
together.
Conclusion
Four years of administration of anti-malarials through 
SMC was not associated with a reduction in IgG levels 
to AMA1, MSP-142 and CSP compared to levels found 
in children who had received SMC for only 2 years sug-
gesting that it is unlikely that these children will be at 
increased risk of malaria when they stop receiving SMC 
at the age of 5 years.
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